Affimed Announces Publication of Comprehensive Preclinical Data Demonstrating the Therapeutic Potential of AFM24 in EGFR-expressing Tumors
Preclinical data demonstrate AFM24s activation of the innate immune system, acting independently of EGFR-expression levels, EGFR-pathway mutations and downstream signal transduction.
- Preclinical data demonstrate AFM24s activation of the innate immune system, acting independently of EGFR-expression levels, EGFR-pathway mutations and downstream signal transduction.
- The published data supported the Investigational New Drug application for the ongoing AFM24 Phase 1/2a dose escalation study.
- The published data were the basis for the Investigational New Drug (IND) clearance for Affimeds ongoing Phase 1/2a study with AFM24 monotherapy in patients with EGFR expressing solid tumors.
- AFM24 is effective against many EGFR-positivetumorcells, regardless of EGFR expression level and KRAS/BRAF mutational status within in vitro studies.